{"product_id":"minimal-residual-disease-market-share-size-trends-industry-analysis-report-by-detection-target-lymphoma-leukemia-solid-tumors-others-by-test-technique-by-end-user-by-region-segment-forecast-2023-2032","title":"Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-User; By Region; Segment Forecast, 2023-2032","description":"\u003cp\u003eMinimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-User; By Region; Segment Forecast, 2023-2032\u003c\/p\u003e\n\n\u003cp\u003eThe global minimal residual disease market size is expected to reach USD 7,131.61 million by 2032, according to a new study by Polaris Market Research. The report “Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-Use; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.\u003c\/p\u003e\n\n\u003cp\u003eThe increased prevalence of hematological malignancy and cancer, as well as rising healthcare spending, are expected to drive growth in the minimal residual disease sector throughout the forecast period. Additionally, rising consumer awareness of customized therapy and expanding investments in MRD research by public and private entities are both assisting in the market’s expansion. Growth in the market is being slowed down by the heavy price of R\u0026amp;D activities.\u003c\/p\u003e\n\n\u003cp\u003eThe appropriate clinical evidence is used to successfully manage cancer therapies to prevent a residue of tumorous cells, and they are also tailored based on unique progression profiles in each individual. The necessity to consider a patient’s unique genetic traits in order to provide effective therapy is being driven by several research studies. For example, in October 2022, Adaptive Biotechnologies, a commercial-stage biotechnology firm aiming to transform the genetics of the adaptive immune system into therapeutic solutions to detect and cure disease, announced a partnership with Epic to substantiate clonoSEQ Assay into Epic’s full EMR system.\u003cbr\u003e\n  \u003cbr\u003e\nAdditionally, the rising number of cancer patients and the rise in R\u0026amp;D spending are the two main factors driving the market. In addition, the industry is expanding due to the growing use of next-generation sequencing technologies. Additionally, the technological developments in diagnostics and therapies brought about by rising R\u0026amp;D expenditures are what’s fueling the market’s expansion.\u003c\/p\u003e\n\n\u003cp\u003eGlobally, the COVID-19 pandemic had an impact on healthcare systems and caused many healthcare facilities to stop providing routine care, putting at-risk cancer patients at serious risk. Although since the outbreak of the COVID-19 pandemic, steps have been taken to increase the number of covid patients admitted and decrease the number of non-covid patients admitted, resulting in treatment delays.\u003c\/p\u003e\n\n\u003cp\u003eMinimal Residual Disease Market Report Highlights\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, leukemia will dominate the market. The primary growth of the market is due to the fact that one person is diagnosed with leukemia every three minutes in the United States.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, flow cytometry is dominating the market due to the high sensitivity and broad applicability of MRD testing enabled by flow cytometry.\u003c\/p\u003e\n\n\u003cp\u003eThe industry sector with the largest revenue share in 2022 was hospitals and specialty clinics. The main factor driving the market is the availability of professionals in hospitals who can help patients choose pertinent MRD tests.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, North America is dominating the market of minimal residual disease due to the rising number of patients in the United States.\u003c\/p\u003e\n\n\u003cp\u003eThe global players with a global presence include Invivoscribe, NeoGenomics Laboratories, Bio-Rad Laboratories, Opko Health, Adaptive Biotechnologies, Natera, Inivata, Sysmex Corporation, and Quest Diagnostics.\u003c\/p\u003e\n\n\u003cp\u003ePolaris Market Research has segmented the Minimal Residual Disease Market report based on detection target, test technique, end-user, and region:\u003c\/p\u003e\n\n\u003cp\u003eMinimal Residual Disease, Detection Target Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eLymphoma\u003c\/p\u003e\n\n\u003cp\u003eLeukemia\u003c\/p\u003e\n\n\u003cp\u003eSolid Tumors\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eMinimal Residual Disease, Test Technique Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eFlow Cytometry\u003c\/p\u003e\n\n\u003cp\u003ePolymerase Chain Reaction (PCR)\u003c\/p\u003e\n\n\u003cp\u003eNext Generation Sequencing (NGS)\u003c\/p\u003e\n\n\u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eMinimal Residual Disease, End-User Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eHospitals and Specialty Clinics\u003c\/p\u003e\n\n\u003cp\u003eLaboratory Centers\u003c\/p\u003e\n\n\u003cp\u003eMinimal Residual Disease, Regional Outlook (Revenue – USD Million, 2019 – 2032)\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003c\/p\u003e\n\n\u003cp\u003eU.S\u003c\/p\u003e\n\n\u003cp\u003eCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003c\/p\u003e\n\n\u003cp\u003eGermany\u003c\/p\u003e\n\n\u003cp\u003eUK\u003c\/p\u003e\n\n\u003cp\u003eFrance\u003c\/p\u003e\n\n\u003cp\u003eItaly\u003c\/p\u003e\n\n\u003cp\u003eSpain\u003c\/p\u003e\n\n\u003cp\u003eRussia\u003c\/p\u003e\n\n\u003cp\u003eNetherlands\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003c\/p\u003e\n\n\u003cp\u003eChina\u003c\/p\u003e\n\n\u003cp\u003eIndia\u003c\/p\u003e\n\n\u003cp\u003eJapan\u003c\/p\u003e\n\n\u003cp\u003eSouth Korea\u003c\/p\u003e\n\n\u003cp\u003eIndonesia\u003c\/p\u003e\n\n\u003cp\u003eMalaysia\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003c\/p\u003e\n\n\u003cp\u003eArgentina\u003c\/p\u003e\n\n\u003cp\u003eBrazil\u003c\/p\u003e\n\n\u003cp\u003eMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eUAE\u003c\/p\u003e\n\n\u003cp\u003eSaudi Arabia\u003c\/p\u003e\n\n\u003cp\u003eIsrael\u003c\/p\u003e\n\n\u003cp\u003eSouth Africa\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 119 Pages \/ MCW16225857","offer_id":47640097554738,"sku":null,"price":5100.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/minimal-residual-disease-market-share-size-trends-industry-analysis-report-by-detection-target-lymphoma-leukemia-solid-tumors-others-by-test-technique-by-end-user-by-region-segment-forecast-2023-2032","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}